

Table 3 The distribution of the suspected agents in DILI patients

Agents	Number of DILI patients	cholestasis injury	hepatocellular injury	Mixed injury	Number of patients taking agent	Incidence of agents	livertox classificatio
Cefoperazone	25	6	12	7	10061	0.25%	D
Voriconazole	24	10	11	3	1798	1.33%	B
Meropenem	22	13	7	2	3858	0.57%	D
Ceftriaxone	15	1	10	4	14889	0.10%	B
Levofloxacin	15	4	9	2	18537	0.08%	A
Fluconazole	14	7	5	2	1203	1.16%	B
Methylprednisolone	11	2	9	0	45025	0.02%	A(HD)
Rosuvastatin	11	0	6	5	8316	0.13%	B
Imipenem and cilastatin	11	9	0	2	2120	0.52%	D
Flurbiprofen	10	3	6	1	33747	0.03%	C
Cefuroxime	10	2	7	1	21464	0.05%	B
Ifosfamide	10	1	8	1	914	1.09%	D
Compound Sulfamethoxazole	9	4	3	2	1466	0.61%	N
Methotrexate	9	1	8	0	1850	0.49%	A
Linezolid	9	4	4	1	2406	0.37%	A
Indomethacin	9	3	5	1	6167	0.15%	C
Cytarabine	8	1	6	1	1482	0.54%	C
Atorvastatin	8	1	5	2	9251	0.09%	A
Caspofungin	7	3	3	1	1005	0.70%	D
Diclofenac	7	0	5	2	7574	0.09%	A
Vancomycin	7	4	3	0	5006	0.14%	B
Lysine Aspirin	6	3	1	2	2992	0.20%	A(HD)
Midazolam	6	1	5	0	59382	0.01%	E
Moxifloxacin	6	1	4	1	2745	0.22%	B
Amikacin	5	3	2	0	408	1.23%	E
Aspirin	5	0	4	1	16653	0.03%	A(HD)
Biapenem	5	2	1	2	1702	0.29%	N
Polaprezinc	5	1	2	2	9416	0.05%	N
Ulinastatin	5	1	4	0	2988	0.17%	N
Mycophenolate.	5	1	4	0	946	0.53%	D
Others	200	68	105	27	/	/	
Total	499	160	264	75			